University Hospitals
Case Medical Center

Monthly News – September 2013

Department of Psychiatry

September 16, 2013 Volume 7, Number 9

In Memoriam:

Dr. John Kennell, Professor Emeritus, passed away peacefully on Tuesday evening, August 27th.

Dr. Kennel joined the Department of Pediatrics at CWRU School of Medicine and Rainbow Babies and Children's Hospital in 1951 and remained here throughout his tenure. Dr. Kennel was a dedicated researcher and pioneer in the study of mothers and babies. Dr. Kennel received the C. Anderson Aldrich Award from the American Academy of Pediatrics that recognizes outstanding contributions to the field of child development. In 2009, the Rainbow Babies and Children's Foundation John Kennell M.D. Chair of Excellence in Pediatrics was created in his honor. After his official retirement, Dr. Kennel remained active as a teacher, mentor and researcher. He will be greatly missed.

10th Annual Suicide Prevention Education Alliance Walk:

When: Sunday October 6, 2013
Where: Cleveland Metroparks Zoo
3900 Wildlife Way
Cleveland, OH 44109
Time: Check-in 6:00 p.m.
All Walk activities end by 8:30 p.m.

To join or donate to SPEA Walk:
Log- on to the SPEA website:
http://spea.donorpages.com/walk/
Click Join a team tab and fill out your information - Our team name is: UH Hospitals Psychiatry

The SPEA Mission is to prevent suicide by educating young people to recognize the warning signs of suicide and to seek professional help for themselves and others.

- Suicide is the second leading cause of death for those 15-24 years of age.
- More teenagers die from suicide than from cancer, heart disease, AIDS, birth defects, stroke, pneumonia, influenza, and chronic lung disease combined.
- Half of all lifetime cases of clinical depression begin by age 14.
- According to The Ohio Department of Mental Health:
  - 20 percent of high school students have seriously considered suicide
  - 14 percent have made a plan
  - 9 percent have made a suicide attempt

BE A LIFESAVER: Personally raise $100 or more to receive a Lifesaver T-shirt at the Walk on October 6th

If you have any questions or would like to participate in the SPEA Walk please email:
Zafar.Zaidi@Uhhospitals.org or
Michelle.John@uhhospitals.org

Grand Rounds:

September 20th:
Speaker: Richard B. Corradi, M.D.
Topic: Schizophrenia as a Human Process

September 27th:
L. Douglas Lenkoski Lecture
Speaker: Lori Raney, M.D.
Topic: The Integration of Primary Care and Behavioral Health: New Roles for Community Psychiatrists

October 4th:
Speaker: Stephen Noffsinger, MD
Topic: Boundary Violations - Down the Slippery Slope and into the Abyss

October 11th:
**** 6th Annual Rocco L. Motto Lecture***
Speaker: Robert L. Findling, MD, MBA
Topic: The Prevention of Pediatric Bipolar Disorder

October 18th:
Speaker: Alan Brown, M.D., M.P.H.
Topic: The Prenatal Environment in Relation to Autism and Other Neuropsychiatric Disorders

October 25th:
Speaker: Gregory X. Boehm, M.D.
Topic: Treating Addiction in Pregnancy

****Reception immediately following the lecture in the Mayer-Haber Conference Room 13-113***

Presentations and Publications:

Dr. John Heather will present a lecture on Depression on **Wednesday, October 9th**, at a Brown Bag Luncheon at Noon in RB&C Amphitheater.

Dr. Chris Bedosky will present a lecture on Understanding OCD on **Monday October 14th**, at a Brown Bag Luncheon at Noon in Bolwell A.

Veta, P., Thompson, L. A., Lee, M., & **Pagano, M. E.** (2013, August). *God-consciousness and youth substance abuse: Influences on chemical dependency treatment.* Symposium presentation at the 108th annual meeting of the American Sociological Association (ASA), New York, NY.

Dr. Maria Pagano's research on AA-related service work for juveniles was referenced in the August issue of the *Grapevine* (AA's national magazine). Her research findings show that juvenile offenders who became active in AA-related service during treatment were less likely to test positive for alcohol and drugs during treatment and had greater psycho-social improvement.

Dr. Phillip Resnick presented a course on Malingering to Wisconsin Prison Staff on August 2nd and a Workshop on Violence Risk Assessment in Lanard, Kansas on August 12, 2013**.**

Project Dawn:

Cuyahoga County Project DAWN is a program for opioid users at risk of death from opioid overdose. The program teaches how to recognize and respond to an overdose and how to administer intranasal Naloxone to reverse an opioid overdose. The program is free of charge and kits containing Naloxone will be distributed free of charge to all participants in the program. Walk-in hours are available at the Cuyahoga County Board of Health in Parma and at the Free Clinic of Greater Cleveland. For more information on the program, call The Metrohealth System at 216-778-2100.

Research Studies:

The Discovery and Wellness Center for Children at University Hospitals Case Medical Center is currently enrolling children and adolescents ages 7-17 for participation in a research study for depression. Some symptoms of depression may include irritability, feeling of worthlessness and loss of interest in activities. Symptoms must occur for a minimum of one month prior to screening. If eligible, patients may receive a study related clinical evaluation, medical tests, and the study drug or a placebo from a doctor who specializes in pediatric mental illness. The investigational drug has not yet been approved for the condition under the study. Duration of the study can last up to 17 weeks. For more information, please contact Becky Weintraub at 216-844-3922.

Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Safety and Efficacy Study of Oral ELND005 as an Adjunctive Maintenance Treatment in Patients with Bipolar I Disorder
Principal Investigator: Joseph R. Calabrese, MD
Gender & Age: Women & Men, ages 18 – 65
Diagnosis: Bipolar I Disorder, and has experienced a mood episode of any polarity within 4 months prior to the Screening Visit and responded to lamotrigine (LTG) or valproic acid (VPA).
Medications: Study subjects will be will be treated with ELND005 and weaned off of any other psychiatric medications they are taking during the open-label phase. Study patients who remain stable during this phase will be eligible for random assignment in the Double-blind Randomization Phase. In the double-bind phase, study patients will be randomly assigned in a 1:1 ratio to receive blinded treatment with either ELND005 or placebo for up to 48 weeks, in addition to either LTG or VPA
Study Details: Up to 72 weeks long
Contact: Carla Conroy at 216-844-2871 or via email: Carla.Conroy@UHHospitals.org

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) 0.1, 0.4, and 0.8mg as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated with Bipolar 1 Disorder in Adult Subjects (TAK-375SL_201)
Principal Investigator: Keming Gao, MD, PhD
Gender & Age: Women & Men, ages 18 - 75

Diagnosis: Bipolar I Disorder, currently depressed
Medications: Lithium and/or one other mood stabilizer (lamotrigine or valproic acid) and/or one atypical antipsychotic (risperidone or olanzapine or aripiprazole or ziprasidone). Subjects may be on one, two or three medications but no more than one from each group. Each subject will be randomized to either TAK -375SL tablet 0.1 mg once daily, TAK-375SL tablet 0.4 mg once daily, TAK-375SL tablet 0.8 mg once daily or placebo once daily.
Study Details: Up to 13 weeks long, visits are once a week for the first month and then bi weekly for an additional month.
Contact: Carla Conroy at 216-844-2871 or via email at Carla.Conroy@UHHospitals.org

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375SL 0.1, 0.4, and 0.8 mg as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar 1 Disorder in Adult Patients (TAK-375SL_203)
Principal Investigator: Keming Gao, MD, PhD
Gender & Age: Women & Men, ages 18 - 75
Diagnosis: Bipolar I Disorder, stable for at least eight weeks with a mood episode within 9 months from screening
Medications: Treatment as usual*. Each subject will be to either TAK -375SL tablet 0.1 mg once daily, TAK-375SL tablet 0.4 mg once daily, TAK-375SL tablet 0.8 mg once daily or placebo once daily.
Study Details: Up to 11 months long, visits are every 2 weeks for the first 2 months and then monthly for an additional 6 months.
Contact: Carla Conroy at 216-844-2871or via email at Carla.Conroy@UHHospitals.org

CAE RCT Study
Do you have any patients who have Bipolar Disorder and have trouble taking all of their bipolar medication?

To participate, individuals must:
1. Have type I or type II bipolar disorder diagnosis for at least 2 years;
2. Have received treatment with at least one evidence-based medication to stabilize mood for at least six months (lithium, anticonvulsant, or antipsychotic mood stabilizer);
3. Be at least 20% or more non-adherent with current BD medication treatment (i.e. lithium, anticonvulsant, or antipsychotic mood stabilizer);

To participate, individuals may NOT:
1. Be children under the age of 18

This is a randomized, controlled trial (RCT) of the **Customized Adherence Enhancement (CAE) psychosocial intervention** (created by Martha Sajatovic MD and Jennifer Levin PhD) vs. broadly-directed, non-individualized education (EDU) in **poorly adherent individuals with bipolar disorder (BD)**. The study is primarily interested in testing whether a (CAE) intervention that addresses the specific reasons for non-adherence among high-risk patients with BD improves treatment adherence and bipolar disorder symptoms compared to EDU. CAE is intended to be a brief adjunct to standard mental health treatment. The proposed project has the potential to greatly advance the care of BD patients who are at greatest risk for poor health outcomes, with findings expected to be generalizable across a variety of treatment settings. ***All individuals will continue to receive treatment as usual with their regular provider(s).***

For more information or to refer a patient contact Melanie Athey at 216-844-2825 or Melanie.Currens@UHhospitals.org

OPT-BD Research Study
Do you see any patients who are **60 years old or older** with **type I Bipolar Disorder** and are currently **sub-optimally responsive** to their prescribed BD treatments?

To participate, individuals must:
1.) Have Type I Bipolar Disorder
2.) Be age 60 or older
3.) Have sub-optimal response to current psychotropic management including:
   a. Behaviors and symptoms of irritability, agitation, mood lability or diminished ability to interact with others in their place of residence
   b. Diminished ability to take care of basic personal needs in their place of residence due to symptoms of BD

To participate, individuals may NOT have:
1.) History of intolerance or resistance to asenapine
2.) Clinical diagnosis of dementia or Mini-mental state (MMSE) < 24
3.) History of TIA, stroke or MI within the past 12 months
4.) Rapid cycling BD defined as 4 or more discrete mood episodes within the previous 12 months.

Participants will receive 12 weeks of open-label asenapine. Each study subject will serve as their own baseline control and mood symptoms will be assessed using standardized measures during the 12 weeks of asenapine therapy. The primary outcome is change from baseline in bipolar mood symptom scores (mania and depression). Secondary outcomes include functional and general health status, global psychopathology, side effects, and extrapyramidal symptoms.

For more information or to refer a patient contact Edna Fuentes-Casiano at 216-844-2104 or Effectiveness.Research@UHhospitals.org

CAE RCT Study

Do you have any patients who have Bipolar Disorder and have trouble taking all of their bipolar medication?

To participate, individuals must:

4. Have type I or type II bipolar disorder diagnosis for at least 2 years;
5. Have received treatment with at least one evidence-based medication to stabilize mood for at least six months (lithium, anticonvulsant, or antipsychotic mood stabilizer);
6. Be at least 20% or more non-adherent with current BD medication treatment (i.e. lithium, anticonvulsant, or antipsychotic mood stabilizer);

To participate, individuals may NOT:

2. Be children under the age of 18

This is a randomized, controlled trial (RCT) of the **Customized Adherence Enhancement (CAE) psychosocial intervention** (created by Martha Sajatovic MD and Jennifer Levin PhD) vs. broadly-directed, non-individualized education (EDU) in **poorly adherent individuals with bipolar disorder (BD)**. The study is primarily interested in testing whether a (CAE) intervention that addresses the specific reasons for non-adherence among high-risk patients with BD improves treatment adherence and bipolar disorder symptoms compared to EDU. CAE is intended to be a brief adjunct to standard mental health treatment. The proposed project has the potential to greatly advance the care of BD patients who are at greatest risk for poor health outcomes, with findings expected to be generalizable across a variety of treatment settings. ***All individuals will continue to receive treatment as usual with their regular provider(s).***

For more information or to refer a patient contact Melanie Athey at 216-844-2825 or Melanie.Currens@UHhospitals.org

Save the Date:

Connor Integrative Medicine Network's Heidi Weiker will present "The Inner Beat of Resilience and Positivity" on
Monday, October 7, 2013
6:30p.m. - 8:00 p.m.
Ahuja Medical Center
Rosenberg Conference Center
3999 Richmond Road.
The event is free, but please call 216-767-8435 to register in advance.

Connor Integrative Medicine network's 2nd Annual Heal the Healer Symposium – Inspiring Purpose, Passion, Performance:
Friday, October 11, 2013
8:45 a.m. – 4:00 p.m.
Signature of Solon Country Club
For more information call:
216-488-4757 or email
Sharon.Allen@UHhospitals.org

PEP Symposium with Bruce D. Perry, M.D., Ph.D
Unique Learning Experience for Educators, Administrators, Counselors and
Anyone who Works with Children Exposed to Trauma and Adversity
Friday, October 18, 2013
Registration: 8:00 a.m.
Program: 8:30 a.m. – 4:00 p.m.
Landerhaven
6111 Landerhaven Drive
Mayfield Heights, Ohio 44124

To learn more about this event, please contact Sharon Parente at sparente@pepcleve.org or by phone at 216-361-4400.

Contact:

Published by University Hospitals Dept. of Psychiatry
DEADLINE FOR NEXT ISSUE:
Friday, October 11, 2013
CONTACT: Kate Kilbane
Phone: 216-844-3658
kate.kilbane@uhhospitals.org